These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25454872)

  • 21. Potentiation of Th1-Type Immune Responses to
    Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
    J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
    Norrby M; Vesikari T; Lindqvist L; Maeurer M; Ahmed R; Mahdavifar S; Bennett S; McClain JB; Shepherd BM; Li D; Hokey DA; Kromann I; Hoff ST; Andersen P; de Visser AW; Joosten SA; Ottenhoff THM; Andersson J; Brighenti S
    Vaccine; 2017 Mar; 35(12):1652-1661. PubMed ID: 28216183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liposomal oral DNA vaccine (mycobacterium DNA) elicits immune response.
    Wang D; Xu J; Feng Y; Liu Y; Mchenga SS; Shan F; Sasaki J; Lu C
    Vaccine; 2010 Apr; 28(18):3134-42. PubMed ID: 20197133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.
    Hussein J; Zewdie M; Yamuah L; Bedru A; Abebe M; Dagnew AF; Chanyalew M; Yohannes AG; Ahmed J; Engers H; Doherty TM; Bang P; Kromann I; Hoff ST; Aseffa A
    Trials; 2018 Jan; 19(1):24. PubMed ID: 29321075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization.
    Thakur A; Rodríguez-Rodríguez C; Saatchi K; Rose F; Esposito T; Nosrati Z; Andersen P; Christensen D; Häfeli UO; Foged C
    Front Immunol; 2018; 9():2825. PubMed ID: 30555488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study.
    Spertini F; Audran R; Lurati F; Ofori-Anyinam O; Zysset F; Vandepapelière P; Moris P; Demoitié MA; Mettens P; Vinals C; Vastiau I; Jongert E; Cohen J; Ballou WR
    Tuberculosis (Edinb); 2013 Mar; 93(2):179-88. PubMed ID: 23219236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcriptomics of the Vaccine Immune Response: Priming With Adjuvant Modulates Recall Innate Responses After Boosting.
    Santoro F; Pettini E; Kazmin D; Ciabattini A; Fiorino F; Gilfillan GD; Evenroed IM; Andersen P; Pozzi G; Medaglini D
    Front Immunol; 2018; 9():1248. PubMed ID: 29922291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant.
    Kamath AT; Rochat AF; Valenti MP; Agger EM; Lingnau K; Andersen P; Lambert PH; Siegrist CA
    PLoS One; 2008; 3(11):e3683. PubMed ID: 18997860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved cellular immune response elicited by a ubiquitin-fused ESAT-6 DNA vaccine against Mycobacterium tuberculosis.
    Wang QM; Kang L; Wang XH
    Microbiol Immunol; 2009 Jul; 53(7):384-90. PubMed ID: 19563397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.
    Reither K; Katsoulis L; Beattie T; Gardiner N; Lenz N; Said K; Mfinanga E; Pohl C; Fielding KL; Jeffery H; Kagina BM; Hughes EJ; Scriba TJ; Hanekom WA; Hoff ST; Bang P; Kromann I; Daubenberger C; Andersen P; Churchyard GJ
    PLoS One; 2014; 9(12):e114602. PubMed ID: 25490675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
    Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
    Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6.
    Langermans JA; Doherty TM; Vervenne RA; van der Laan T; Lyashchenko K; Greenwald R; Agger EM; Aagaard C; Weiler H; van Soolingen D; Dalemans W; Thomas AW; Andersen P
    Vaccine; 2005 Apr; 23(21):2740-50. PubMed ID: 15780721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the Mincle and TLR3 receptor using the dual agonist cationic adjuvant formulation 9 (CAF09) induces humoral and polyfunctional memory T cell responses in calves.
    Thakur A; Andrea A; Mikkelsen H; Woodworth JS; Andersen P; Jungersen G; Aagaard C
    PLoS One; 2018; 13(7):e0201253. PubMed ID: 30063728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis.
    Wang QL; Pan Q; Ma Y; Wang K; Sun P; Liu S; Zhang XL
    Vaccine; 2009 Nov; 27(48):6712-22. PubMed ID: 19733584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4⁺ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs.
    Commandeur S; van den Eeden SJ; Dijkman K; Clark SO; van Meijgaarden KE; Wilson L; Franken KL; Williams A; Christensen D; Ottenhoff TH; Geluk A
    Vaccine; 2014 Jun; 32(29):3580-8. PubMed ID: 24837764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential of Cationic Liposomes as Adjuvants/Delivery Systems for Tuberculosis Subunit Vaccines.
    Khademi F; Taheri RA; Momtazi-Borojeni AA; Farnoosh G; Johnston TP; Sahebkar A
    Rev Physiol Biochem Pharmacol; 2018; 175():47-69. PubMed ID: 29700609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants.
    Chen L; Xu M; Wang ZY; Chen BW; Du WX; Su C; Shen XB; Zhao AH; Dong N; Wang YJ; Wang GZ
    FEMS Immunol Med Microbiol; 2010 Jun; 59(1):42-52. PubMed ID: 20298499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice.
    Geluk A; van den Eeden SJ; van Meijgaarden KE; Dijkman K; Franken KL; Ottenhoff TH
    Vaccine; 2012 Dec; 30(52):7513-21. PubMed ID: 23103299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection.
    Trentini MM; de Oliveira FM; Gaeti MP; Batista AC; Lima EM; Kipnis A; Junqueira-Kipnis AP
    Vaccine; 2014 Jul; 32(34):4324-32. PubMed ID: 24951861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX.
    Niu H; Hu L; Li Q; Da Z; Wang B; Tang K; Xin Q; Yu H; Zhang Y; Wang Y; Ma X; Zhu B
    Vaccine; 2011 Nov; 29(51):9451-8. PubMed ID: 22024175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.